"Administration of a non-sterile drug intended to be sterile may result in serious and potentially life-threatening adverse health consequences including infections and sepsis," the FDA warned
The compound is highly specific for GLP-1R, as it is unable to activate the closely related human receptors for glucagon, glucagon-like peptide-2 (GLP-2) and secretin
The gradual titration protocol exists specifically to manage this
It is not for human consumption, therapeutic use, or diagnostic use
These programs can significantly reduce the out-of-pocket cost if you meet the eligibility criteria, which typically include having no insurance coverage for GLP-1s and meeting certain income requirements
Although primarily indicated for diabetes management, it has shown promising results in clinical trials for weight loss in obese or overweight individuals